489 related articles for article (PubMed ID: 12912815)
21. P2Y12, a new platelet ADP receptor, target of clopidogrel.
Herbert JM; Savi P
Semin Vasc Med; 2003 May; 3(2):113-22. PubMed ID: 15199474
[TBL] [Abstract][Full Text] [Related]
22. Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): in vitro effects on platelets.
Bryant J; Post JM; Alexander S; Wang YX; Kent L; Schirm S; Tseng JL; Subramanyam B; Buckman B; Islam I; Yuan S; Sullivan ME; Snider M; Morser J
Thromb Res; 2008; 122(4):523-32. PubMed ID: 18495218
[TBL] [Abstract][Full Text] [Related]
23. Deaggregation is an integral component of the response of platelets to ADP in vitro: kinetic studies of literature and original data.
Maayani S; Tagliente TM; Schwarz T; Craddock-Royal B; Alcala C; Marrero G; Martinez R
Platelets; 2001 Aug; 12(5):279-91. PubMed ID: 11487380
[TBL] [Abstract][Full Text] [Related]
24. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs.
Foster CJ; Prosser DM; Agans JM; Zhai Y; Smith MD; Lachowicz JE; Zhang FL; Gustafson E; Monsma FJ; Wiekowski MT; Abbondanzo SJ; Cook DN; Bayne ML; Lira SA; Chintala MS
J Clin Invest; 2001 Jun; 107(12):1591-8. PubMed ID: 11413167
[TBL] [Abstract][Full Text] [Related]
25. Shear-induced global thrombosis test of native blood: pivotal role of ADP allows monitoring of P2Y12 antagonist therapy.
Saraf S; Wellsted D; Sharma S; Gorog DA
Thromb Res; 2009 Sep; 124(4):447-51. PubMed ID: 19476973
[TBL] [Abstract][Full Text] [Related]
26. Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy.
Smith SM; Judge HM; Peters G; Armstrong M; Fontana P; Gaussem P; Daly ME; Storey RF
Platelets; 2006 Jun; 17(4):250-8. PubMed ID: 16769602
[TBL] [Abstract][Full Text] [Related]
27. Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits.
Wong PC; Crain EJ; Watson CA; Jiang X; Hua J; Bostwick JS; Ogletree ML; Schumacher WA; Rehfuss R
J Cardiovasc Pharmacol; 2007 May; 49(5):316-24. PubMed ID: 17513951
[TBL] [Abstract][Full Text] [Related]
28. P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease.
Bierend A; Rau T; Maas R; Schwedhelm E; Böger RH
Br J Clin Pharmacol; 2008 Apr; 65(4):540-7. PubMed ID: 17995973
[TBL] [Abstract][Full Text] [Related]
29. Platelet aggregation and adenosine diphosphate/adenosine triphosphate receptors: a historical perspective.
Packham MA; Mustard JF
Semin Thromb Hemost; 2005 Apr; 31(2):129-38. PubMed ID: 15852216
[TBL] [Abstract][Full Text] [Related]
30. Increased platelet purinergic sensitivity in peripheral arterial disease--a pilot study.
Braun OO; Jagroop A; Wang L; Mikhailidis DP; Burnstock G; Erlinge D
Platelets; 2005 Aug; 16(5):261-7. PubMed ID: 16011976
[TBL] [Abstract][Full Text] [Related]
31. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
Béres BJ; Tóth-Zsámboki E; Vargová K; László A; Masszi T; Kerecsen G; Préda I; Kiss RG
Thromb Haemost; 2008 Nov; 100(5):829-38. PubMed ID: 18989527
[TBL] [Abstract][Full Text] [Related]
32. Aspirin resistance and a single gene.
Jefferson BK; Foster JH; McCarthy JJ; Ginsburg G; Parker A; Kottke-Marchant K; Topol EJ
Am J Cardiol; 2005 Mar; 95(6):805-8. PubMed ID: 15757620
[TBL] [Abstract][Full Text] [Related]
33. Association between platelet P2Y12 haplotype and risk of cardiovascular events in chronic coronary disease.
Schettert IT; Pereira AC; Lopes NH; Hueb WA; Krieger JE
Thromb Res; 2006; 118(6):679-83. PubMed ID: 16405973
[TBL] [Abstract][Full Text] [Related]
34. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.
Hasegawa M; Sugidachi A; Ogawa T; Isobe T; Jakubowski JA; Asai F
Thromb Haemost; 2005 Sep; 94(3):593-8. PubMed ID: 16268477
[TBL] [Abstract][Full Text] [Related]
35. PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy.
Smith SM; Judge HM; Peters G; Armstrong M; Dupont A; Gaussem P; Storey RF
Platelets; 2005 Sep; 16(6):340-5. PubMed ID: 16194864
[TBL] [Abstract][Full Text] [Related]
36. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel.
Malinin A; Pokov A; Swaim L; Kotob M; Serebruany V
Methods Find Exp Clin Pharmacol; 2006 Jun; 28(5):315-22. PubMed ID: 16845449
[TBL] [Abstract][Full Text] [Related]
37. Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes.
Behan MW; Fox SC; Heptinstall S; Storey RF
Platelets; 2005 Mar; 16(2):73-80. PubMed ID: 15823862
[TBL] [Abstract][Full Text] [Related]
38. Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): pharmacodynamic and pharmacokinetic characterization.
Post JM; Alexander S; Wang YX; Vincelette J; Vergona R; Kent L; Bryant J; Sullivan ME; Dole WP; Morser J; Subramanyam B
Thromb Res; 2008; 122(4):533-40. PubMed ID: 18539312
[TBL] [Abstract][Full Text] [Related]
39. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay.
Schäfer A; Weinberger S; Flierl U; Eigenthaler M; Störk S; Walter U; Ertl G; Bauersachs J
Thromb Haemost; 2008 Oct; 100(4):618-25. PubMed ID: 18841284
[TBL] [Abstract][Full Text] [Related]
40. ADP-induced platelet activation.
Puri RN; Colman RW
Crit Rev Biochem Mol Biol; 1997; 32(6):437-502. PubMed ID: 9444477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
